Working to Eradicate Gynecologic Cancers

David Gardner Mutch, MD

Ira and Judith Gall Prof. of OB/GYN, Dir. Div. of Gyn. Onc.
Washington University School of Medicine
4911 Barnes Hospital Plaza
NA
St. Louis, MO
USA 63110

Papers:
6 Clinical implications for MSI, MLH1 methylation analysis and IHC in Lynch screening for endometrial cancer patients: an analysis of 940 endometrioid endometrial cancer cases from the GOG0210 study 45 Clinicopathologic features associated with defective DNA mismatch repair (MMR): a GOG0210 cohort study of 1041 endometrioid endometrial cancer cases 84 Universal screening for Lynch syndrome in endometrial cancer results in increased acceptance of genetic counseling and testing 105 Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer 144 Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project 148 Cell-based therapy in ovarian cancer: improved adenoviral transduction strategy of human mesenchymal stem cells as tumor-homing drug factories 158 Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model 164 Outcomes for partial metabolic response on post therapy positron emission tomography for cervical cancer: role of surgical intervention 245 Gyn/Onc partnership with sarcoma center yields superior clinical trial enrollments for uterine leiomyosarcoma patients 332 Antibody fragments targeting the tumor marker mesothelin selectively deliver TRAIL therapeutics and cause efficient ovarian cancer cell death 387 Awareness of the association between obesity and perioperative risk among newly diagnosed endometrial cancer patients 511 Unveiling novel mutations in the DNA-binding domain of FOXA2 in endometrioid endometrial cancers